Key Details
Annual ROE
-299.91%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
May 09, 2023Recent annual earnings:
Feb 14, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Apr 24, 2023Analyst ratings
Recent major analysts updates
22 Nov '21 HC Wainwright & Co.
BuyScreeners with VLON included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Vallon Pharmaceuticals doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Vallon Pharmaceuticals?
- What is the ticker symbol for Vallon Pharmaceuticals?
- Does Vallon Pharmaceuticals pay dividends?
- What sector is Vallon Pharmaceuticals in?
- What industry is Vallon Pharmaceuticals in?
- What country is Vallon Pharmaceuticals based in?
- When did Vallon Pharmaceuticals go public?
- Is Vallon Pharmaceuticals in the S&P 500?
- Is Vallon Pharmaceuticals in the NASDAQ 100?
- Is Vallon Pharmaceuticals in the Dow Jones?
- When was Vallon Pharmaceuticals's last earnings report?
- When does Vallon Pharmaceuticals report earnings?
- Should I buy Vallon Pharmaceuticals stock now?
What is the primary business of Vallon Pharmaceuticals?
As of April 21, 2023, Vallon Pharmaceuticals, Inc. was acquired by GRI Bio, Inc., in a reverse merger transaction. Vallon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. The company's lead investigational product candidate is ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. The company was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
What is the ticker symbol for Vallon Pharmaceuticals?
The ticker symbol for Vallon Pharmaceuticals is NASDAQ:VLON
Does Vallon Pharmaceuticals pay dividends?
No, Vallon Pharmaceuticals does not pay dividends
What sector is Vallon Pharmaceuticals in?
Vallon Pharmaceuticals is in the Healthcare sector
What industry is Vallon Pharmaceuticals in?
Vallon Pharmaceuticals is in the Biotechnology industry
What country is Vallon Pharmaceuticals based in?
Vallon Pharmaceuticals is headquartered in United States
When did Vallon Pharmaceuticals go public?
Vallon Pharmaceuticals's initial public offering (IPO) was on 10 February 2021
Is Vallon Pharmaceuticals in the S&P 500?
No, Vallon Pharmaceuticals is not included in the S&P 500 index
Is Vallon Pharmaceuticals in the NASDAQ 100?
No, Vallon Pharmaceuticals is not included in the NASDAQ 100 index
Is Vallon Pharmaceuticals in the Dow Jones?
No, Vallon Pharmaceuticals is not included in the Dow Jones index
When was Vallon Pharmaceuticals's last earnings report?
Vallon Pharmaceuticals's most recent earnings report was on 9 May 2023
When does Vallon Pharmaceuticals report earnings?
The date for Vallon Pharmaceuticals's next earnings report has not been announced yet
Should I buy Vallon Pharmaceuticals stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions